(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of 46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Stoke Therapeutics's revenue in 2024 is $8,780,000.On average, 4 Wall Street analysts forecast STOK's revenue for 2024 to be $582,130,657, with the lowest STOK revenue forecast at $430,161,772, and the highest STOK revenue forecast at $694,556,145. On average, 3 Wall Street analysts forecast STOK's revenue for 2025 to be $507,303,808, with the lowest STOK revenue forecast at $397,286,115, and the highest STOK revenue forecast at $694,556,145.
In 2026, STOK is forecast to generate $1,440,509,445 in revenue, with the lowest revenue forecast at $430,161,772 and the highest revenue forecast at $3,196,810,417.